 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- | ALS-2200 / J&J, Vertex, BMS
New P2a trial: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Dec 19, 2017
P2a, N=20, Completed, Sponsor: Alios Biopharma Inc.
- ALS-2200 / J&J, Vertex, BMS
Phase classification: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Oct 31, 2017
P2a, N=20, Completed, Sponsor: Alios Biopharma Inc.
Phase classification: P2 --> P2a
- | ALS-2200 / J&J, Vertex, BMS
Trial completion, Trial primary completion date: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (clinicaltrials.gov) - May 5, 2015
P2, N=23, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Phase classification: P2 --> P2a Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> May 2014
- ||| ALS-2200 / J&J, Vertex, BMS
Trial completion: First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Jan 26, 2015
P1, N=71, Completed, Sponsor: Alios Biopharma Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> May 2014 Active, not recruiting --> Completed
- ALS-2200 / J&J, Vertex, BMS
Trial completion, Enrollment change, Trial primary completion date: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Jul 12, 2014
P2, N=10, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Aug 2013 --> Feb 2014
- | ALS-2200 / J&J, Vertex, BMS
Trial completion: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Jun 26, 2014
P2, N=20, Completed, Sponsor: Alios Biopharma Inc.
Active, not recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Aug 2013 --> Feb 2014 Active, not recruiting --> Completed
- | ALS-2200 / J&J, Vertex, BMS
Enrollment closed: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (clinicaltrials.gov) - Apr 1, 2014
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ALS-2200 / J&J, Vertex, BMS
P2 data, P2a data: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C (clinicaltrials.gov) - Nov 12, 2013
P2, N=20, Active, not recruiting, Sponsor: Alios Biopharma Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | ALS-2200 / J&J, Vertex, BMS
Enrollment closed: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Jun 17, 2013
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | ALS-2200 / J&J, Vertex, BMS
New P2 trial: A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C (clinicaltrials.gov) - Apr 25, 2013
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- | ALS-2200 / J&J, Vertex, BMS
Enrollment change: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Mar 6, 2013
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Active, not recruiting N=150 --> 20
- | ALS-2200 / J&J, Vertex, BMS
P2 data, P2a data: A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C (clinicaltrials.gov) - Feb 10, 2013
P2, N=20, Active, not recruiting, Sponsor: Alios Biopharma Inc.
- || ALS-2200 / J&J, Vertex, BMS
Enrollment closed: First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Jan 21, 2013
P1, N=80, Active, not recruiting, Sponsor: Alios Biopharma Inc.
N=150 --> 20 Recruiting --> Active, not recruiting
- | ALS-2200 / J&J, Vertex, BMS
New P2 trial: A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na (clinicaltrials.gov) - Nov 13, 2012
P2, N=20, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- ||| ALS-2200 / J&J, Vertex, BMS
New P1 trial: First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - May 1, 2012
P1, N=80, Active, not recruiting, Sponsor: Alios Biopharma Inc.